ICON (ICLR) vs Revvity (RVTY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Revvity (RVTY) has outperformed ICON (ICLR) over the past year, gaining 65.8% versus a loss of 12.1%. Over five years, RVTY leads with a -10.4% price change compared with -40.3% for ICLR. Revvity is the larger company by market cap ($16.98 billion vs $12.69 billion), about 1.3 times the size.
On valuation, ICON trades at a lower forward P/E (13.9x vs 25.8x for Revvity). Revvity pays a dividend yielding 0.18%, while ICON does not currently pay one. Revvity converts more of its revenue into profit, with a net margin of 8.4% versus 2.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICLR | RVTY |
|---|---|---|
| Share price | $164.50 | $152.16 |
| Market cap | $12.69B | $16.98B |
| 1-day change | +0.26% | -0.94% |
| YTD return | -9.95% | +57.27% |
| 1-year return | -12.09% | +65.81% |
| 5-year return | -40.34% | -10.40% |
| P/E ratio (TTM) | 173.16 | 72.80 |
| Forward P/E | 13.93 | 25.82 |
| EPS (TTM) | $0.95 | $2.09 |
| Dividend yield | 0.00% | 0.18% |
| Annual dividend | $0.00 | $0.28 |
| Revenue (latest FY) | $8.25B | $2.86B |
| Revenue growth (YoY) | +0.76% | +3.67% |
| Net income (latest FY) | $229.34M | $241.20M |
| Gross margin | 26.37% | — |
| Operating margin | 5.37% | 12.49% |
| Net margin | 2.78% | 8.45% |
| 52-week high | $203.91 | $166.25 |
| 52-week low | $66.57 | $81.22 |
| Distance from 52-week high | -19.33% | -8.48% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +12.10% | -10.71% |
| Average volume | 822.57K | 1.79M |
| Shares outstanding | 77.15M | 111.59M |
| Employees | 40,200 | 11,000 |
| Sector | Healthcare | Industrials |
| Industry | Diagnostics & Research | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RVTY has outperformed ICLR by 77.9 percentage points over the past year.
- ICON trades at a higher earnings multiple (173.2x vs 72.8x trailing P/E).
- Revvity is more profitable, keeping 8.4 cents of every revenue dollar as net income versus 2.8 cents for ICON.
- The two companies sit in different sectors: ICON in Healthcare and Revvity in Industrials.
About ICON
ICLR stock →ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Healthcare · Diagnostics & Research · 40,200 employees
About Revvity
RVTY stock →Revvity, Inc. provides health sciences solutions, technologies, and services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,000 employees
ICLR vs RVTY FAQ
Which is bigger, ICON or Revvity?
Revvity (RVTY) is larger, with a market capitalization of $16.98B compared with $12.69B for ICON (ICLR).
Which stock has performed better over the past year, ICLR or RVTY?
RVTY returned +65.81% over the past 12 months, compared with -12.09% for ICLR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ICLR or RVTY?
RVTY has the lower trailing P/E at 72.8, versus 173.2 for ICLR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, ICON or Revvity?
Revvity pays a dividend yielding 0.18%, while ICON does not currently pay a regular dividend.
Are ICON and Revvity in the same industry?
No. ICON is in the Healthcare sector, while Revvity is in Industrials.